
All Providers:
Chiropractors:
Community Alternatives Program Providers:
Dental Providers:
Durable Medical Equipment Providers:
Home Health Agencies:
Hospice Providers:
Hospitals:
Independent Practitioner Program Providers:
Local Education Agencies:
Mental Health Providers:
Nursing Facility Providers:
Optometrists:
Osteopaths:
Physicians:
Private Duty Nursing Providers:
Podiatrists:
Prescribers and Pharmacy Providers:
Seminars on general Medicaid billing guidelines are scheduled for January 2005. Registration information and a list of dates and site locations for the seminars will be published in the December 2004 general Medicaid bulletin.
EDS, 1-800-688-6696 or 919-851-8888
Information related to the implementation of the new Medicaid Management Information System, NCLeads, scheduled for implementation in mid 2006 can be found online at http://ncleads.dhhs.state.nc.us. Please refer to this website for information, updates, and contact information related to the NCLeads system.
Thomas Liverman, Provider Relations
Office of MMIS Services
919- 855-3112
All providers participating in the Medicaid program are required to submit to the Division of Medical Assistance (DMA), Third Party Recovery Section a quarterly Credit Balance Report indicating balances due to Medicaid. Providers must report any outstanding credits owed to Medicaid that have not been reported previously on a Medicaid Credit Balance Report. However, hospital and nursing facility providers are required to submit a report every calendar quarter even if there are no credit balances. The report must be submitted no later than 30 days following the end of the calendar quarter (March 31, June 30, September 30, and December 31).
The Medicaid Credit Balance Report is used to monitor and recover "credit balances" owed to the Medicaid program. A credit balance results from an improper or excess payment made to a provider. For example, refunds must be made to Medicaid if a provider is paid twice for the same service (e.g., by Medicaid and a medical insurance policy, by Medicare and Medicaid, by Medicaid and a liability insurance policy, if the patient liability was not reported in the billing process or if computer or billing errors occur).
For the purpose of completing the report, a Medicaid Credit Balance is the amount determined to be refundable to the Medicaid program. When a provider receives an improper or excess payment for a claim, it is reflected in the provider’s accounting records (patient accounts receivable) as a "credit." However, credit balances include money due to Medicaid regardless of its classification in a provider's accounting records. If a provider maintains a credit balance account for a stipulated period (e.g., 90 days) and then transfers the account or writes it off to a holding account, this does not relieve the provider of liability to the Medicaid program. The provider is responsible for identifying and repaying all monies owed the Medicaid program.
The Medicaid Credit Balance Report requires specific information on each credit balance on a claim-by-claim basis. The reporting form provides space for 15 claims but may be reproduced as many times as necessary to accommodate all the credit balances being reported. Specific instructions for completing the report are on the reverse side of the reporting form.
Submitting the Medicaid Credit Balance Report does not result in the credit balances automatically being reimbursed to the Medicaid program. A check is the preferred form of satisfying the credit balances; the check must be made payable to EDS and sent to EDS with the required documentation for a refund. If an adjustment is to be made to satisfy the credit balance, an adjustment form must be completed and submitted to EDS with all the supporting documentation for processing.
|
Submit |
Submit |
Submit |
|
Third Party Recovery Section |
EDS |
EDS |
Submit only the completed Medicaid Credit Balance Report to DMA. Do not send refund checks or adjustment forms to DMA. Do not send the Credit Balance Report to EDS. Failure to submit a Medicaid Credit Balance Report will result in the withholding of Medicaid payments until the report is received.
Anita Ray, Third Party Recovery Section
DMA, 919-647-8100
Effective with date of service August 16, 2004, the Medicaid maximum reimbursement rate for the following Community Alternatives Program (CAP) services was increased. This was an interim rate increase that will be effective through December 2004. Results from a pending audit of PCS providers may result in a subsequent rate change. Providers are to be notified of any further rate changes in future general Medicaid bulletins.
Reimbursement
In addition, S5150 HQ, CAP-MR/DD Respite Care (group of 2 to 3 clients) has been revised effective October 1, 2004 to $2.74 per 15 minute unit.
|
Procedure Code
|
Description |
Reimbursement Rate |
|---|---|---|
|
T1000 |
CAP/C Nursing Services |
$9.11/15 min unit |
|
T1005TD |
CAP/AIDS Respite Care – Nursing Level RN |
$9.11/15 min unit |
|
T1005TE |
CAP/AIDS Respite Care – Nursing Level LPN |
$9.11/15 min unit |
|
T1005TD |
CAP-MR/DD Respite Care – Nursing Level RN |
$9.11/15 min unit |
|
T1005TE |
CAP-MR/DD Respite Care – Nursing Level LPN |
$9.11/15 min unit |
Pat Jeter, Rate Setting
DMA, 919-855-4200
Effective with date of service October 1, 2004, the following dental procedure codes have been added to the NC Medicaid Dental Program. These additions were published on September 1, 2004 in Special Bulletin VI: Dental Services Coverage Policy and Billing Guidelines.
|
CDT-4 |
|
Reimbursement |
|---|---|---|
|
D0170 |
Re-evaluation – limited, problem focused *use as a follow-up exam for a specific problem that has been evaluated previously using D0140 *document in the patient’s chart the nature of the emergency and the treatment provided |
$20.00 |
|
D1204 |
Topical application of fluoride (prophylaxis not included) – adult *limited to recipients 13 through 20 years old |
$15.44 |
|
D3230 |
Pulpal therapy (resorbable filling) – anterior, primary tooth *limited to recipients under age 6 *not allowed for the same tooth on the same date of service as D3220 |
$150.00 |
|
D3240 |
Pulpal therapy (resorbable filling) – posterior, primary tooth *limited to recipients under age 9 *allowed for primary second molars only *not allowed for the same tooth on the same date of service as D3220 |
$200.00 |
|
D3320 |
Bicuspid (excluding final restoration) *limited to recipients under age 21 *not allowed for the same tooth on the same date of service as D3220 |
$259.57 |
The following procedure codes were end-dated effective with date of service September 30, 2004.
|
Procedure code |
Description |
|---|---|
|
D2910 |
Recement inlay |
|
D2920 |
Recement crown |
|
D3110 |
Pulp cap – direct (excluding final restoration) |
In addition, the following changes are effective with date of service October 1, 2004:
Providers are reminded to bill their usual and customary charges rather than the Medicaid rate. For coverage criteria and additional billing guidelines, please refer to Clinical Coverage Policy 4A, Dental Services.
Dr. Ron Venezie, Dental Director
DMA, 919-855-4280
The Division of Medical Assistance (DMA) has a new website for the NC Medicaid Dental Program. This website includes links to the current dental and orthodontic policy manuals as well as the current dental fee schedule. You also will find a list of frequently asked questions, instructions for the Automated Voice Response (AVR) system, and a list of tips for correcting the most common dental claim denials. The Dental Program website also includes links to those Medicaid forms that are most often used by dental providers. Please let us know if you have suggestions for other helpful links that could be included.
Dr. Ron Venezie, Dental Director
DMA, 919-855-4280
In order to comply with the Centers for Medicare and Medicaid Services’ coding changes, codes A4323, sterile saline, 1000 ml, and K0409, sterile water, 1000 ml, will be end-dated on November 30, 2004. They will be replaced with code A4217, sterile water/saline, 500 ml.
Effective with date of service December 1, 2004, providers must bill for sterile water/saline with code A4217. The maximum reimbursement rate will be $2.66. Prior approval is not required. However, a Certificate of Medical Necessity and Prior Approval form must be completed regardless of the requirement for prior approval.
EDS, 1-800-688-6696 or 919-851-8888
Reimbursement Rate Increase for Private Duty Nursing Services
Effective with date of service October 1, 2004, the Medicaid maximum reimbursement rate for In-Home Private Duty Nursing is being changed to $9.11 per 15 minute unit. This is an annual rate increase per the State Plan.
Effective with date of service November 30, 2004, the following HCPCS codes will be end-dated to comply with the national standard codes mandated by the Health Insurance Portability and Accountability Act (HIPAA). The new codes will become effective December 1, 2004.
HCPCS Code List
|
Current |
New |
Description |
Billing |
Maximum Reimbursement Rate |
|---|---|---|---|---|
|
A4214 |
A4216 |
Sterile /saline or water, 10ml |
10ml |
$ .40 |
|
A4323 |
A4217 |
Sterile /saline or water, 500ml |
500ml |
2.66 |
|
A4621 |
A7525 |
Tracheostomy mask each |
Each |
2.07 |
|
A7526 |
Tracheostomy tube, collar and holder |
Each |
3.37 |
|
|
A4622 |
A7520 |
Tracheostomy/laryngectomy tube, non-cuffed, polyvinylchloride (pvc), silicone or equal each |
Each |
47.48 |
|
A7521 |
Tracheostomy/laryngectomy tube, cuffed polyvinylchloride (pvc), sil1cone or equal each. |
Each |
47.05 |
|
|
A7522 |
Tracheostomy/laryngectomy tube, stainless steel or equal (sterilizable or reusable), each |
Each |
45.16 |
|
|
A6422 |
A6443 |
Conforming bandage, non-elastic, knitted/woven, non-sterile, width greater than or equal to three inches and less than 5 inches, per yard |
Per yard |
.29 |
|
A6424 |
A6444 |
Conforming bandage, non-elastic, knitted/woven, nonsterile greater than or equal to five inches per yard. |
Per yard |
.56 |
|
A6426 |
A6446 |
Conforming bandage, nonelastic, knitted/woven, sterile, width greater than or equal to three inches and less than 5 inches, per yard |
Per yard |
.41 |
|
A6428 |
A6447 |
Conforming bandage, nonelastic, knitted/woven, sterile, greater than or equal to five inches per yard |
Per yard |
.67 |
|
A6430 |
A6449 |
Light compression bandage, elastic, knitted/woven, width greater than or equal to three inches and less than 5 inches, per yard |
Per yard |
1.75 |
|
A6432 |
A6450 |
Light compression bandage, elastic, knitted/woven, width greater than or equal to 5 inches, per yard |
Per yard |
1.00 |
|
A6440 |
A6456 |
Zinc paste impregnated bandage, nonelastic, knit/woven, width greater than or equal to 3 inches and less than 5 inches, per yard |
Per yard |
1.28 |
|
B4084 |
B4086 |
Gastrostomy/jejunostomy tube any type |
Each |
17.09 |
|
K0621 |
A6407 |
Packing strips, non-impregnatal, up to 2 inched wide |
Each |
1.88 |
|
S8181 |
See A7526 Above |
Tracheostomy tube, collar and holder |
Each |
3.37 |
|
W4651 |
Use current code A4253 |
Blood glucose test strips |
50/pkg |
33.22 |
EDS, 1-800-688-6696 or 919-851-8888
The Home Health Fee Schedule has been updated to reflect the following rates for all home health visits. The update is effective for dates of service July 1, 2004. EDS will generate automated adjustments for claims processed and paid at the old rate. Providers do not need to submit adjustment requests.
|
Revenue Code |
Home Health Services |
Billing Unit |
Maximum Rate Reimbursement |
|---|---|---|---|
|
420 |
Physical Therapy |
1 visit |
$99.94 |
|
424 |
Physical Therapy - Evaluation |
1visit |
99.94 |
|
430 |
Occupational Therapy |
1 visit |
99.94 |
|
434 |
Occupational Therapy - Evaluation |
1visit |
99.94 |
|
440 |
Speech Therapy |
1 visit |
99.94 |
|
444 |
Speech Therapy - Evaluation |
1visit |
99.94 |
|
550 |
Observation/Evaluation of stable patient |
1 visit |
101.41 |
|
551 |
Skilled Nursing Visit Prefilling insulin syringes |
1 visit |
101.41 |
|
559 |
Skilled Nursing Visit for Prefilling medicine planners |
1 visit |
101.41 |
|
570 |
Home Health Aide |
1 visit |
46.39 |
|
580 |
Skilled Nursing Visit for Venipuncture |
1 visit |
101.41 |
|
581 |
Skilled Nursing Visit for Denied by Medicare for dually-eligible patient |
1 visit |
101.41 |
|
589 |
Skilled Nursing Visit meeting Medicare criteria |
1 visit |
101.41 |
|
590 |
Skilled Nursing Visit/Not Otherwise Classified |
1 visit |
101.41 |
EDS, 1-800-688-6696 or 919-851-8888
The N.C. Medicaid program does not routinely cover observation charges for hysterectomies. These charges are covered only in situations where a patient exhibits an uncommon or unusual reaction or other postoperative complications that require monitoring or treatment beyond the usual provided in the immediate post operative period. When observation charges are billed and no records are included with the claim, the claim will be denied for medical records to substantiate necessity for the service. Providers will receive the denial EOB 1396 "Observation is not routinely allowed. Submit records to review for medical necessity, include: History and Physical, Operative records, Pathology report and Discharge summary."
EDS 1-800-688-6696 or 919-851-8888
Effective with date of service September 17, 2004, the rates for some services provided by the Independent Practitioners Program were changed. Below is a list of the changes.
Refer to Clinical Policy #10B (previously numbered as #8G) for additional information and for a complete list of billing codes.
Note: Not all rates are changing at this time. Please refer to future bulletin articles for further information. Providers should continue to bill their usual and customary charges.
|
Procedure Code |
Maximum Reimbursement Rate |
|---|---|
|
29075 |
$ 69.79 |
|
29085 |
74.33 |
|
29105 |
72.68 |
|
29125 |
55.15 |
|
29126 |
68.14 |
|
29130 |
33.91 |
|
29131 |
44.49 |
|
29240 |
54.90 |
|
29260 |
45.37 |
|
29280 |
45.93 |
|
29405 |
72.21 |
|
29425 |
78.52 |
|
29505 |
63.99 |
|
29515 |
55.72 |
|
29530 |
47.73 |
|
29540 |
32.73 |
|
31502 |
73.36 |
|
31720 |
87.02 |
|
92065 |
31.39 |
|
92510 |
123.43 |
|
92526 |
74.77 |
|
92551 |
9.69 |
|
92552 |
15.41 |
|
92567 |
18.49 |
|
92569 |
14.09 |
|
92571 |
13.43 |
|
92572 |
3.19 |
|
92576 |
15.63 |
|
92583 |
31.14 |
|
92587 |
52.81 |
|
92588 |
70.00 |
|
92590 |
39.94 |
|
92591 |
59.99 |
|
92592 |
17.56 |
|
92593 |
26.31 |
|
92594 |
18.98 |
|
92595 |
28.82 |
|
92610 |
115.35 |
|
94010 |
28.81 |
|
94060 |
49.52 |
|
94150 |
18.77 |
|
94200 |
19.09 |
|
94240 |
32.00 |
|
94375 |
31.80 |
|
94657 |
63.34 |
|
95831 |
21.38 |
|
95832 |
18.76 |
|
95833 |
31.75 |
|
95834 |
38.23 |
|
97010 |
4.00 |
|
97012 |
13.71 |
|
97016 |
12.88 |
|
97018 |
5.98 |
|
97020 |
4.33 |
|
97022 |
13.51 |
|
97024 |
5.32 |
|
97026 |
4.33 |
|
97028 |
5.37 |
|
97032 |
14.37 |
|
97033 |
18.91 |
|
97034 |
12.95 |
|
97035 |
11.30 |
|
97036 |
21.05 |
|
97110 |
26.09 |
|
97112 |
26.31 |
|
97116 |
22.55 |
|
97124 |
20.23 |
|
97140 |
24.28 |
|
97504 |
27.74 |
|
97520 |
25.65 |
|
97530 |
26.61 |
|
97533 |
23.75 |
|
97535 |
27.30 |
|
97542 |
25.43 |
|
97601 |
35.01 |
|
97602 |
15.77 |
|
97703 |
22.85 |
|
97750 |
26.31 |
Laurie Edwards, Financial Management
DMA, 919-855-4200
Effective with date of service September 17, 2004, the rates for some services provided by Local Education Agencies (LEAs) were changed. Below is a list of the changes. This table replaces information published in the April 2004 general Medicaid bulletin.
The below are maximum reimbursement rates; however, providers must bill their usual and customary charges. Schools that bill Medicaid are only paid the federal share of the Medicaid reimbursement rate listed below. Reimbursement rates will change as the Federal Financial Participation (FFP) percentage changes.
Refer to the Clinical Coverage Policy #10C (previously numbered at 8H) for additional information on billing for LEA services and a complete list of billing codes.
Note: Not all rates are changing at this time. Please refer to future bulletin articles for further information.
|
Procedure Code |
Maximum Reimbursement |
|---|---|
|
29075 |
$ 69.79 |
|
29085 |
74.33 |
|
29105 |
72.68 |
|
29125 |
55.15 |
|
29126 |
68.14 |
|
29130 |
33.91 |
|
29131 |
44.49 |
|
29240 |
54.90 |
|
29260 |
45.37 |
|
29280 |
45.93 |
|
29405 |
72.21 |
|
29505 |
63.99 |
|
29515 |
55.72 |
|
29530 |
47.73 |
|
29540 |
32.73 |
|
90801 |
139.49 |
|
90802 |
148.15 |
|
90804 |
59.98 |
|
90806 |
90.19 |
|
90808 |
134.73 |
|
90810 |
64.21 |
|
90812 |
97.28 |
|
90814
|
141.27
|
|
90846
|
87.47
|
|
90853
|
29.40
|
|
92065
|
31.39
|
|
92510
|
123.43
|
|
92526
|
74.77
|
|
92551
|
9.69
|
|
92552
|
15.41
|
|
92567
|
18.49
|
|
92569
|
14.09
|
|
92572
|
3.19
|
|
92576
|
15.63
|
|
92583
|
31.14
|
|
92585
|
89.93
|
|
92587
|
52.81
|
|
92588
|
70.00
|
|
92590
|
39.94
|
|
92591
|
59.99
|
|
92592
|
17.56
|
|
92593
|
26.31
|
|
92594
|
18.98
|
|
92595
|
28.82
|
|
95831 |
21.38 |
|
95832 |
18.76 |
|
95833 |
31.75 |
|
95834 |
38.23 |
|
96100 |
62.40 |
|
96110 |
10.22 |
|
96111 |
131.50 |
|
96115 |
62.40 |
|
96117 |
62.40 |
|
97110 |
26.09 |
|
97112 |
26.31 |
|
97116 |
22.55 |
|
97140 |
24.28 |
|
97504 |
27.74 |
|
97520 |
25.65 |
|
97530 |
26.61 |
|
97533 |
23.75 |
|
97535 |
27.30 |
|
97542 |
25.43 |
|
97703 |
22.85 |
|
97750 |
26.31 |
Laurie Edwards, Financial Management
DMA, 919-855-4200
Seminars for the expansion of provider types for Outpatient Behavioral Health Services are scheduled for December 2004. This seminar will focus on the expansion of access to services for Medicaid eligible recipients by increasing the provider community and the age group that they serve.
Providers are encouraged to arrive 30 minutes before the seminar begins to complete registration. Unregistered providers are welcome to attend if space is available. No food or drinks will be provided.
Providers may register for the seminars by completing and submitting the Outpatient Behavioral Health Services Registration form or through by Online Registration.
The December 2004 Special Bulletin VII, Outpatient Behavioral Health Services Provided by Direct Enrolled Providers, will be used as the primary training document for the seminar. The special bulletin will be available on DMA’s website beginning December 2004 at http://www.ncdhhs.gov/dma/bulletin/index.htm. Please print the special bulletin and bring it to the seminar.
|
Tuesday, Decemer 7, 2004 Park Inn Gateway Conference Center |
Wednesday, December 8, 2004 Blue Ridge Community College |
|
Thursday, December 9, 2004 Greenville Hilton
|
Friday, December 10, 2004 Wake Med Andrews Conference Center |
Park Inn Gateway Conference Center – Hickory, North Carolina
Take I-40 to exit 123. Follow signs to Highway 321 North. Take the first exit (Hickory exit) and follow the ramp to the stoplight. Turn right at the light onto Highway 70. The Gateway Conference Center is on the right.
Blue Ridge Community College, Bo Thomas Auditorium – Flat Rock, North Carolina
Take I-40 to Asheville. Travel east on I-26 to exit 22. Turn right and then take the next right. Follow the signs to Blue Ridge Community College. Turn left at the large Blue Ridge Community College sign. The college is located on the right. Take the first right-hand turn into the parking lot for the Bo Thomas Auditorium.
Greenville Hilton – Greenville, North Carolina
Take Highway 264 east to Greenville. Turn right onto Allen Road in Greenville. Travel approximately 2 miles. Allen Road becomes Greenville Boulevard/Alternate 264. Follow Greenville Boulevard for 2½ miles to the Hilton Greenville, which is located on the right.
WakeMed Andrews Conference Center – Raleigh, North Carolina
Take the I-440 Raleigh Beltline to exit 13A, New Bern Avenue.
Paid parking ($3.00 maximum per day) is available on the top two levels of parking deck P3. To reach the parking deck, turn left at the fourth stoplight on New Bern Avenue, and then turn left at the first stop sign. Parking for oversized vehicles is available in the overflow lot for parking deck P3. Handicapped accessible parking is available in parking lot P4, directly in front of the conference center.
To enter the Andrews Conference Center, follow the sidewalk toward New Bern Avenue past the Medical Office Building to entrance E2 of the William F. Andrews Center for Medical Education. A map of the WakeMed campus is available online at http://www.wakemed.org.
Illegally parked vehicles will be towed. Parking is not permitted at East Square Medical Plaza, Wake County Human Services or in parking lot P4 (except for handicapped accessible parking).
EDS, 1-800-688-6696 or 919-851-8888
On October 1, 2004, the Division of Medical Assistance (DMA) will begin a new Medical Data Sets (MDS) Validation Program as a component of the Medicaid Case Mix Reimbursement System. All facilities participating in the Medicaid Case Mix Reimbursement System are required to participate in the MDS Validation Program. The overall goal of the Case Mix Reimbursement System is to align payments with the level of care needed by the residents in the facility. Completion of the MDS reports is a very important function of the nursing facility staff and ensures that the nursing facility receives accurate payments from the N.C. Medicaid program.
The MDS Validation Program provides DMA and the nursing facility with assurance that the Medicaid payments are accurately based on the recorded medical and functional needs of the nursing facility resident as documented in the medical record. The MDS Validation Program replaces the FL2 and FL12 utilization review program performed by the facility staff and contract physicians, which was discontinued as of September 30, 2003.
DMA has contracted with Myers and Stauffer, LLP, to provide registered nurse reviewers to conduct onsite MDS reviews of each nursing facility in North Carolina. The reviews were scheduled to begin on October 1, 2004. All of the reviews will be completed by September 30, 2005. This first year (October 1, 2004 through September 30, 2005) of reviews are considered as educational reviews and are intended to assist facility staff in understanding the process and the requirements for MDS supportive documentation.
Important Definitions for the MDS Validation Program
RUG-III Reimbursement System – Medicaid uses the RUG III system to assign the facility Case Mix Index (CMI) rate. RUG III groups classify residents into 34 groups that use similar quantities of resources defined as nursing time, therapy time, and nursing assistant time. There are 108 MDS 2.0 elements that determine the RUG III classification system.
Case Mix – refers to a combination of different individual resident profiles seen in a specific setting or facility.
Case Mix Index (CMI) – each RUG-III group is assigned a weight, or numeric score, which reflects the relative resources predicted to provide care to the resident. The higher the case mix index, the greater the resource requirement for the resident.
Resident Roster – identifies all non-discharged residents and includes information on the MDS RUG-III elements transmitted on the sample set of assessments. In addition, it provides a summary of the number of MDS records in each RUG-III category.
Supportive Documentation Guidelines
DMA uses the Supportive Documentation Guidelines approved by the Centers for Medicare and Medicaid Services (CMS) to define the supporting documentation necessary to verify a RUG-III item during an MDS review.
MDS Validation Program Protocols
1. The list of residents or resident roster is produced on a Case Mix Index Report (CMI Report) every quarter on the "snapshot date" and sent to the facility. The "snapshot dates" are March 31, June 30, September 30, and December 31. For a facility review occurring in October 2004, the review sample will be drawn from the CMI Report dated June 30, 2004. For a facility review, occurring in February 2005, the review sample will be drawn from the CMI Report of residents in the facility dated September 30, 2004.
2. The sample will be drawn from all residents listed on the final CMI report regardless of payer source.
3. Both the primary and expanded samples shall include a minimum of 80 percent Medicaid recipients.
4. In the second year of case mix reviews, facilities will experience an expanded review when the primary assessment sample results in an unsupported percent are equal to or greater than the state threshold. This expanded review will include an additional 10 percent of the residents on the final CMI report or an additional 10 assessments, whichever is greater.
5. The results of the MDS Validation Program may result in re-rugging and a change in the case mix index rate for the nursing facility, as defined below.
MDS Review Process
1. Nursing facilities will be notified by the contract nurse reviewers both by phone and by fax three (3) business days prior to the visit.
2. An entrance conference will be held with the nursing facility administrator, the MDS coordinator, and any other facility personnel the administrator selects to discuss the overall objectives of the review and to allow the facility personnel to ask questions.
3. The nurse reviewer will prepare a list of the MDS's and resident records selected for review and ask the facility personnel to pull the records. If possible, the primary sample will include at least one assessment from each of the seven RUG-III classification groups.
4. The review begins immediately after the entrance conference. The reviewers will use the MDS documentation guidelines as issued by CMS (http://www.cms.hhs.gov/).
5. The reviewer will verify the MDS items and determine if the RUG-III category reported on the Final Case Mix Report is supported with documentation in the medical record.
6. Documentation for the activities of daily living (ADL's) must reflect 24/7 of the observation periods to verify the submitted values on the MDS.
7. Immediately following the review of the MDS assessments, the medical records, and other supportive documentation, the nurse reviewers will hold an exit interview with the facility staff to review preliminary results. Any unresolved issues or trends will be identified and discussed.
8. No supporting documentation will be accepted after the close of the exit conference.
9. A case mix review summary letter will be mailed to the provider by the nurse reviewers from Myers and Stauffer indicating the results of the review.
10. DMA reserves the right to conduct follow-up reviews as needed. These reviews would occur no earlier than 120 days following the exit interview.
Delinquent MDS Assessment:
Any assessment with an R2b date greater than 121 days from the previous R2b date will be deemed delinquent and assigned a RUG-III code of BC1, which is the lowest possible case mix index.
Unsupported MDS Assessment
The MDS is unsupported when the MDS nurse reviewers do not find adequate documentation for the RUG-III Classification level in the patient record. An unsupported MDS assessment can result in a different RUG-III classification from the one submitted by the facility.
Effect of Unsupported Thresholds
The following resources are available to facility staff for questions related to the MDS and MDS Validation Program
MDS State Contact – For all questions related to coding.
Cindy DePorter, Division of Facility Services
919-715-1872, ext. 214
MDS Help Desk
919-715-1872
Myers and Stauffer’s Help Desk – For questions other
than coding issues.
Documentation Guidelines
1-800-763-2278
MDS Validation Program Oversight and Administration
Margaret Comin, RN, Facility Unit Manager
DMA, 919-855-4350
The following table lists the FDA-approved-drugs currently covered by the N.C. Medicaid program when the drugs are provided in a physician’s office for the FDA-approved indications. This list replaces all previously published lists. Rates are effective with the April 1, 2004 date of service and reflect a change to 90 percent AWP. Since the effect is both increases and decreases to the rates, systematic adjustments will be made to align paid claims with these fees retroactive to April 1, 2004 for claims paid between April 1, 2004 and implementation of these rates.
Physicians will continue to bill on the CMS-1500 claim form using the appropriate drug code and indicating the specified number of units administered. Providers must bill their usual and customary charges.
An asterisk (*) indicates that an invoice must be submitted with the CMS-1500 claim form. An invoice must be submitted with each claim. The paper invoice must indicate the name of the recipient, the recipient’s Medicaid identification number, the name of the medication, the dosage given, the National Drug Code (NDC) number from the vial(s) used, the number of vials used, and the cost per dose. Providers must indicate the number of units given in block 24G on the CMS-1500 claim form. Payment is based in accordance with Medicaid’s State Plan for reimbursement. Providers will be reimbursed the lower of the invoice price or maximum allowable fee on file.
Injectable Drug List
|
Invoice Required |
Procedure Code |
Description |
Maximum Reimbursement Rate |
|---|---|---|---|
|
|
J0130 |
Abciximab 10 mg |
$486.02 |
|
|
J1120 |
Acetazolamide Sodium, up to 500 mg (Diamox) |
19.44 |
|
J0150 |
Adenosine I.V., 6 mg (Adenocard) |
36.85 |
|
|
|
J0152 |
Adenosine, 30 mg (Adenoscan) |
72.40 |
|
|
J0170 |
Adrenalin, Epinephrine, up to 1 ml ampule |
2.22 |
|
* |
J3490 |
Agalsidase Beta, 1mg (Fabrazyme) |
4500.00 |
|
|
P9047 |
Albumin (human), 25%, 50 ml |
52.20 |
|
|
P9041 |
Albumin (human), 5%, 50 ml |
13.78 |
|
|
J9015 |
Aldesleukin, per single use vial (Proleukin, IL-2, Interleukin) 22 million I.U. |
695.81 |
|
|
J0215 |
Alefacept 0.5 mg, injection (Amevive) |
29.85 |
|
|
J0205 |
Alglucerase, per 10 units (Ceredase) |
35.56 |
|
|
J0256 |
Alpha 1 Proteinase Inhibitor Human A, 10 mg (Prolastin) |
2.52 |
|
|
J2997 |
Alteplase recombinant, 1 mg |
34.77 |
|
|
J0207 |
Amifostine 500 mg (Ethyol) |
429.13 |
|
|
S0072 |
Amikacin Sulfate (100 mg) |
14.06 |
|
|
S0016 |
Amikacin Sulfate 500 mg (Amikin) |
16.88 |
|
|
J0280 |
Aminophyllin, up to 250 mg |
1.00 |
|
|
J1320 |
Amitriptyline HCL, up to 20 mg (Elavil, Enovil) |
2.28 |
|
|
J0300 |
Amobarbital, up to 125 mg (Amytal) |
2.52 |
|
|
J0288 |
Amphotericin B cholesteryl sulfate complex, 10 mg |
14.40 |
|
|
J0287 |
Amphotericin B lipid complex, 10 mg |
20.70 |
|
|
J0289 |
Amphotericin B liposome, 10 mg |
33.91 |
|
|
J0285 |
Amphotericin B, 50 mg (Amphocin, Fungizone IV) |
10.48 |
|
|
J0295 |
Ampicillin Sodium/Sulbactam Sodium, per 1.5 gm (Unasyn) |
7.03 |
|
|
J0290 |
Ampicillin, up to 500 mg (Omnipen-N, Totacillin-N) |
1.57 |
|
|
J0350 |
Anistreplase, per 30 units (Eminase) |
2552.02 |
|
|
J7197 |
Antithrombin II (human) per I.U. (Throbate III) |
1.19 |
|
|
J0395 |
Arbutamine HCL, 1 mg (GenESA) |
172.80 |
|
|
J9017 |
Arsenic Trioxide 1mg (Trisenox) |
35.10 |
|
|
J9020 |
Asparaginase, 10,000 units (Elspar) |
59.32 |
|
|
J0460 |
Atropine Sulfate, up to 0.3 mg |
0.78 |
|
|
J2910 |
Aurothioglucose, up to 50 mg (Solganal) |
16.40 |
|
|
J0456 |
Azithromycin, 500 mg. (Zithromax) |
24.20 |
|
|
Q0144 |
Azithromycin, oral suspension 1 unit = 1 gm packet (Zithromax), only oral drug on list |
23.02 |
|
|
J0476 |
Baclofen, for intrathecal trial, 50 mcg (Lioresal for intrathecal trial) |
75.60 |
|
|
J0475 |
Baclofen, Kit 1*20 ml. Amp. (10 mg/20ml. 500 meg/ml.) |
221.40 |
|
* |
J3490 |
Baclofen, Kit 2*5 ml. Amp. (10 mg./5 ml. 2000 meg/ml.) |
464.40 |
|
* |
J3490 |
Baclofen, Kit 4*5 ml. Amp. (10 mg./5ml. 2000 meg/ml.) |
815.40 |
|
|
J9031 |
BCG live (intravesical) per installation (Tice, TheraCys) |
151.70 |
|
|
J0702 |
Betamethasone Acetate and Betamethasone Sodium Phosphate, per 3 mg |
4.72 |
|
|
J0704 |
Betamethasone Sodium Phosphate, per 4 mg |
1.02 |
|
|
J0520 |
Bethanechol Chloride, mytonachol or urecholine, up to 5 mg (Urecholine) |
5.06 |
|
|
J9040 |
Bleomycin Sulfate, 15 units (Blenoxane) |
172.80 |
|
|
S0115 |
Bortezomib 3.5 mg (Velcade) |
1076.63 |
|
|
J0585 |
Botulinum toxin type A, per unit (Botox) |
4.69 |
|
|
J0945 |
Brompheniramine Maleate, 10mg |
0.90 |
|
|
J0595 |
Butorphanol Tartrate, 1mg (Stadol) |
4.17 |
|
|
J0636 |
Calcitriol, 0.1 mcg (Calcijex) |
1.31 |
|
|
J0610 |
Calcium Gluconate, per 10 ml (Kaleinate) |
0.96 |
|
|
J0620 |
Calcium Glycerophosphate and Calcium Lactate, per 10 ml (Calphosan) |
6.08 |
|
|
J9045 |
Carboplatin, 50 mg (Paraplatin) |
140.92 |
|
|
J9050 |
Carmustine, 100 mg (BiCNU) |
129.01 |
|
|
J0690 |
Cefazolin Sodium, 500 mg (Ancef, Kefzol, Zolicef) |
2.13 |
|
|
J0692 |
Cefepime HCL, 500 mg (Maxiprene) |
7.70 |
|
|
J0698 |
Cefotaxime Sodium, per gm (Claforan) |
9.90 |
|
|
J0694 |
Cefoxitin Sodium, 1 gm (Mefoxin) |
10.13 |
|
|
J0713 |
Ceftazidime per 500 mg (Fortaz, Tazidime) |
6.40 |
|
|
J0715 |
Ceftizoxime Sodium, per 500 mg (Cefizox) |
4.70 |
|
|
J0696 |
Ceftriaxone Sodium, per 250 mg (Rocephin) |
14.14 |
|
|
J0697 |
Cefuroxime Sodium, per 750 mg (Kefurox, Zinacef) |
6.08 |
|
|
J1890 |
Cephalothin Sodium, up to 1 gm (Keflin) |
9.72 |
|
|
J0710 |
Cephapirin Sodium, up to 1 gm (Cefadyl) |
1.33 |
|
J0720 |
Chloramphenicol Sodium Succinate, up to 1 gm |
6.84 |
|
|
|
J1990 |
Chlordiazepoxide HCL, up to 100 mg (Librium) |
23.68 |
|
|
J0390 |
Chloroquine HCL, up to 250 mg (Aralen) |
18.65 |
|
|
J1205 |
Chlorothiazide Sodium, 500 mg (Diuril Sodium) |
9.94 |
|
|
J2400 |
Chlorprocaine HCL 30 ml (Nesacaine, Nesacaine-MPF) |
6.06 |
|
|
J3230 |
Chlorpromazine HCL up to 50 mg (Thorazine) |
4.17 |
|
|
J0725 |
Chorionic Gonadotropin, per 1,000 USP units |
2.93 |
|
|
J0740 |
Cidofovir 375 mg (Vistide) |
799.20 |
|
|
J0743 |
Cilastatin Sodium Imipenem, per 250 mg (Primaxin IM, Primaxin IV) |
15.04 |
|
|
S0023 |
Cimetadine HCL, 300 mg (Tagamet) |
1.34 |
|
|
J0744 |
Ciprofloxacin for IV infusion, 200 mg (Cipro) |
12.97 |
|
|
J9062 |
Cisplatin, 50 mg (Platinol AQ) |
75.60 |
|
|
J9060 |
Cisplatin, powder or solution, per 10 mg (Platinol, Plantinol AQ) |
15.12 |
|
|
J9065 |
Cladribine, per 1 mg (Leustatin) |
48.60 |
|
|
J0735 |
Clonidine Hydrochloride, 1 mg |
52.25 |
|
|
J0745 |
Codeine Phosphate, per 30 mg |
0.48 |
|
|
J0760 |
Colchicine, 1 mg |
6.70 |
|
|
J0770 |
Colistimethate Sodium, up to 150 mg (Coly-Mycin M) |
51.30 |
|
|
J0800 |
Corticotropin, up to 40 units (Acthar, ACTH) |
88.05 |
|
|
J0835 |
Cosyntropin, per 0.25 mg (Cortrosyn) |
17.28 |
|
|
J3420 |
Cyanocobalamin, vitamin B 12, 1000 mcg |
0.13 |
|
|
J9096 |
Cyclophosphamide Lyophilized 1 gm (Cytoxan Lyophilized) |
46.29 |
|
|
J9093 |
Cyclophosphamide Lyophilized, 100 mg (Cytoxan Lyophilized) |
5.29 |
|
|
J9097 |
Cyclophosphamide Lyophilized, 2gm |
92.60 |
|
|
J9091 |
Cyclophosphamide, 1.0 gm (Cytoxan, Neosar) |
43.33 |
|
|
J9070 |
Cyclophosphamide, 100 mg (Cytoxan, Neosar) |
5.43 |
|
|
J9092 |
Cyclophosphamide, 2.0 gm (Cytoxan, Neosar) |
86.63 |
|
|
J9080 |
Cyclophosphamide, 200 mg (Cytoxan, Neosar) |
10.31 |
|
|
J9090 |
Cyclophosphamide, 500 mg (Cytoxan, Neosar) |
21.65 |
|
|
J9094 |
Cyclophosphamide, Lyophilized, 200 mg (Cytoxan Lyophilized) |
10.58 |
|
|
J9095 |
Cyclophosphamide, Lyophilized, 500 mg (Cytoxan Lyophilized) |
23.14 |
|
|
J9100 |
Cytarabine 100 mg (Cytosar-U) |
3.02 |
|
|
J9110 |
Cytarbine, 500 mg (Cytosar-U) |
8.10 |
|
|
J7070 |
D5W, 1000 cc |
10.40 |
|
|
J9130 |
Dacarbazine 100 mg (DTIC-Dome) |
12.02 |
|
|
J9140 |
Dacarbazine 200 mg (DTIC-Dome) |
20.90 |
|
|
J7513 |
Daclizumab, 25 mg (Zenapax) |
402.73 |
|
|
J9120 |
Dactinomycin, .5 mg (Cosmegen) |
13.14 |
|
|
J1645 |
Dalteparin, per 2500 I.U. (Fragmin) |
14.87 |
|
|
J0880 |
Darbepoetin Alfa, 5 mcg (Aranesp) |
22.45 |
|
|
J9151 |
Daunorubicin Citrate Liposomal, 10 mg (DaunoXome) |
61.20 |
|
|
J9150 |
Daunorubicin HCL, 10 mg (Cerubidine) |
70.33 |
|
|
J0895 |
Deferoxamine Mesylate, 500 mg (Desferal) |
14.81 |
|
|
J9160 |
Denileukin Diftitox, 300mcg (Ontak) |
1260.90 |
|
|
J1000 |
Depoestradiol Cypionate, up to 5 mg |
1.80 |
|
|
J7340 |
Dermal and epidermal tissue of human origin, with or without bioengineered or |
27.76 |
|
|
J2597 |
Desmopression Acetate per 1 mcg (DDAVP) |
3.27 |
|
|
J1094 |
Dexamethasone Acetate 1 mg |
0.68 |
|
|
J1100 |
Dexamethosone Sodium Phosphate, 1 mg (Cortastat, Dalalone) |
0.10 |
|
|
J1190 |
Dexrazoxane HCL, 250 mg (Zinecard) |
221.65 |
|
|
J7110 |
Dextran 75, 500 ml |
13.46 |
|
|
J7042 |
Dextrose 5%/Normal Saline (500 ml = 1 unit) |
8.95 |
|
|
J7060 |
Dextrose 5%/Water (500 ml = 1 unit) |
8.57 |
|
|
J3360 |
Diazepam, up to 5 mg (Valium, Zetran) |
0.82 |
|
|
J1730 |
Diazoxide, up to 300 mg (Hyperstat IV) |
116.48 |
|
|
J0500 |
Dicyclomine HCL, up to 20 mg (Bentyl, Dilomine, Antispas) |
16.16 |
|
|
J9165 |
Diethylstilbestrol Diphosphate, 250 mg (Stilphostrol) |
13.65 |
|
|
J1160 |
Digoxin, up to 0.5 mg (Lanoxin) |
1.69 |
|
|
J1110 |
Dihydroergotamine Mesylate, up to 1 mg |
38.16 |
|
|
J1240 |
Dimenhydrinate, up to 50 mg |
0.36 |
|
|
J0470 |
Dimercaprol, per 100 mg |
22.43 |
|
|
J1200 |
Diphenhydramine HCL, up to 50 mg (Benadryl) |
1.52 |
|
|
J1245 |
Dipyridamole, per 10 mg (Persantine IV) |
5.40 |
|
|
J1212 |
DMSO, Dimethyl Sulfoxide, 50%, 50 ml |
42.26 |
|
J1250 |
Dobutamine HCL, 250 mg (Dobutrex) |
4.49 |
|
|
|
J9170 |
Docetaxel, 20 mg (Taxotere) |
339.08 |
|
|
J1260 |
Dolasetron Mesylate, 10 mg (Anzemet) |
15.59 |
|
|
J1270 |
Doxercalciferol, 1 mg (Hectorol) |
5.21 |
|
|
J1810 |
Droperidol and Fentanyl Citrate, up to 2 ml ampule (Innovar) |
8.95 |
|
|
J1790 |
Droperidol, up to 5 mg (Inapsine) |
2.66 |
|
|
J1180 |
Dyphylline, up to 500 mg (Lufyllin, Dilor) |
8.54 |
|
|
J0600 |
Edetate Calcium Disodium up to 1000 mg |
41.78 |
|
|
J1650 |
Enoxaparin Sodium, 10 mg (Lovenox) |
6.13 |
|
|
J9178 |
Epirubicin HCl, 2 mg (Ellence) |
26.18 |
|
|
Q9920 |
EPO, per 1000 units, Patient HCT 20 or less |
12.02 |
|
|
Q9921 |
EPO, per 1000 units, Patient HCT 21 |
12.02 |
|
|
Q9922 |
EPO, per 1000 units, Patient HCT 22 |
12.02 |
|
|
Q9923 |
EPO, per 1000 units, Patient HCT 23 |
12.02 |
|
|
Q9924 |
EPO, per 1000 units, Patient HCT 24 |
12.02 |
|
|
Q9925 |
EPO, per 1000 units, Patient HCT 25 |
12.02 |
|
|
Q9926 |
EPO, per 1000 units, Patient HCT 26 |
12.02 |
|
|
Q9927 |
EPO, per 1000 units, Patient HCT 27 |
12.02 |
|
|
Q9928 |
EPO, per 1000 units, Patient HCT 28 |
12.02 |
|
|
Q9929 |
EPO, per 1000 units, Patient HCT 29 |
12.02 |
|
|
Q9930 |
EPO, per 1000 units, Patient HCT 30 |
12.02 |
|
|
Q9931 |
EPO, per 1000 units, Patient HCT 31 |
12.02 |
|
|
Q9932 |
EPO, per 1000 units, Patient HCT 32 |
12.02 |
|
|
Q9933 |
EPO, per 1000 units, Patient HCT 33 |
12.02 |
|
|
Q9934 |
EPO, per 1000 units, Patient HCT 34 |
12.02 |
|
|
Q9935 |
EPO, per 1000 units, Patient HCT 35 |
12.02 |
|
|
Q9936 |
EPO, per 1000 units, Patient HCT 36 |
12.02 |
|
|
Q9937 |
EPO, per 1000 units, Patient HCT 37 |
12.02 |
|
|
Q9938 |
EPO, per 1000 units, Patient HCT 38 |
12.02 |
|
|
Q9939 |
EPO, per 1000 units, Patient HCT 39 |
12.02 |
|
|
Q9940 |
EPO, per 1000 units, Patient HCT 40 |
12.02 |
|
|
Q0136 |
Epoetin Alpha (for non ESRD use) per 1000 units (Epogen) |
12.02 |
|
|
J1325 |
Epoprostenol 0.5 mg |
17.11 |
|
J1330 |
Ergonovine Maleate, up to 0.2 mg |
4.45 |
|
|
|
J1364 |
Erythromycin Lactobionate, per 500 mg (Erythrocin) |
3.32 |
|
|
J1380 |
Estradiol Valerate, up to 10 mg |
0.50 |
|
|
J1390 |
Estradiol Valerate, up to 20 mg |
1.00 |
|
J0970 |
Estradiol Valerate, up to 40 mg (Delestrogen) |
1.54 |
|
|
|
J1410 |
Estrogen Conjugated per 25 mg(Premarin intravenous) |
58.28 |
|
J1435 |
Estrone, per 1 mg (Estone Aqueous, Estronol, etc.) |
0.54 |
|
|
|
J1436 |
Etidronate Disodium, per 300 mg (Didronel) |
72.9 |
|
|
J9181 |
Etoposide, 10 mg (VePesid) |
1.62 |
|
|
J9182 |
Etoposide, 100 mg (VePesid) |
16.20 |
|
|
J7193 |
Factor IX (Antihemophilic Factor, Purified, non-recombinant) – per I.U. |
1.06 |
|
|
J7195 |
Factor IX(Antihemophilic Factor recombinant)per I.U. |
1.06 |
|
|
J7194 |
Factor IX complex, per I.U. |
0.35 |
|
|
Q0187 |
Factor VIIa (Coagulation Factor, recombinant) per 1.2 mg (Novoseven) |
15.93 |
|
|
J7190 |
Factor VIII (anti-hemophilic factor, human) per I.U. |
0.83 |
|
|
J7191 |
Factor VIII (anti-hemophilic factor, porcine) per I.U. |
1.94 |
|
|
J7192 |
Factor VIII(anti-hemophilic factor recombinant)per I.U. |
1.20 |
|
|
J3010 |
Fentanyl Citrate, 0.1 mg (2 ml) (Sublimaze) |
0.88 |
|
|
J1440 |
Filgrastim , 300 mcg/1ml (Neupogen) |
176.11 |
|
|
J1441 |
Filgrastim , 480 mcg/1.6ml (Neupogen) |
297.54 |
|
|
J9200 |
Floxuridine, 500 mg (FUDR) |
129.6 |
|
|
J9185 |
Fludarabine Phosphate, 50 mg (Fludara) |
337.33 |
|
|
J9190 |
Fluorouracil, 500 mg (Adrucil) |
1.96 |
|
|
J2680 |
Fluphenazine Decanoate up to 25mg(Prolixin Decanoate) |
8.93 |
|
|
J1455 |
Foscarnet Sodium, per 1000 mg (Foscavir) |
12.38 |
|
|
J9395 |
Fulvestrant, 25 mg (Faslodex) |
82.98 |
|
|
J1940 |
Furosemide, up to 20 mg (Lasix, Furomide M.D.) |
0.93 |
|
|
J1570 |
Ganciclovir Sodium, 500 mg (Cytovene) |
33.40 |
|
|
J7310 |
Ganciclovir, Long-acting Implant, 4.5 mg (Vitrasert) |
4500.00 |
|
|
J9201 |
Gemcitabine HCl. 200 mg (Gemzar) |
114.64 |
|
|
J1580 |
Gentamicin (Garamycin Sulfate) up to 80 mg (Gentamicin Sulfate, Jenamicin) |
1.80 |
|
|
J1610 |
Glucagon Hydrochloride, per 1 mg |
43.20 |
|
|
J1600 |
Gold Sodium Thiomaleate, up to 50 mg (Myochrysine) |
12.81 |
|
|
J1620 |
Gonadorelin Hydrochloride, per 100 mcg (Factrel) |
191.35 |
|
|
J9202 |
Goserelin Acetate Implant, per 3.6 mg (Zoladex) |
422.99 |
|
|
J1626 |
Granisetron Hydrochloride, 100 mcg (Kytril) |
17.57 |
|
|
J1631 |
Haloperidol Decanoate, per 50 mg (Haldol Decanoate – 50) |
8.64 |
|
|
J1630 |
Haloperidol Lactate, up to 5 mg (Haldol) |
6.47 |
|
|
J1642 |
Heparin Sodium, per 10 units (Heparin Lock Flush) |
0.05 |
|
|
J1644 |
Heparin Sodium, per 1000 units |
0.38 |
|
|
J3470 |
Hyaluronidase, up to 150 units (Wydase) |
19.50 |
|
|
J0360 |
Hydralazine HCL, up to 20 mg (Apresoline) |
15.19 |
|
|
J1700 |
Hydrocortisone Acetate, up to 25 mg |
0.32 |
|
|
J1710 |
Hydrocortisone Sodium Phosphate, up to 50 mg |
5.27 |
|
|
J1720 |
Hydrocortisone Sodium Succinate, up to 100 mg |
2.36 |
|
|
J1170 |
Hydromorphone, up to 4 mg (Dilaudid) |
1.47 |
|
|
J3410 |
Hydroxyzine HCL, up to 25 mg (Vistaril, Vistaject-25, Hyzine-50) |
1.14 |
|
|
J7320 |
Hylan G-F 20, 16 mg, for intra-arterial injection (Synvisc) |
220.87 |
|
|
J1980 |
Hyoscyamine Sulfate, up to 0.25 mg (Levsin) |
8.11 |
|
|
J7130 |
Hypertonic Saline Solution, 50 or 100 mEq, 20 cc vial) |
0.50 |
|
|
J1742 |
Ibutilide Fumarate 1 mg. (Corvert) |
238.12 |
|
|
J9211 |
Idarubicin Hydrochloride, 5 mg (Idamycin) |
397.84 |
|
|
J9208 |
Ifosfamide, 1 gm (Ifex) |
142.46 |
|
|
J1785 |
Imiglucerase, per unit (Cerezyme) |
3.56 |
|
|
J1745 |
Infliximab, 10 mg (Remicade) |
62.24 |
|
J1815 |
Insulin, up to 100 units (Regular, NPH, Lente, or Ultralente)) |
0.10 |
|
|
|
J9213 |
Interferon, Alfa-2A, Recombinant, 3 million units (Roferon-A) |
33.05 |
|
|
J9214 |
Interferon, Alfa-2B, Recombinant, 1 million units (Intron A) |
14.09 |
|
|
J9212 |
Interferon, Alfacon-1, Recombinant, 1 mcg (Infergen) |
3.88 |
|
|
J9215 |
Interferon, Alfa-N3, (human leukocyte derived) 250,000 IU (Alferon N) |
7.74 |
|
|
J9216 |
Interferon, Gamma 1-B, 3 million units (Actimmune) |
198.21 |
|
|
J9206 |
Irinotecan, 20 mg (Camptosar) |
138.07 |
|
|
J1750 |
Iron Dextran, 50 mg (Infed) |
16.97 |
|
|
J1756 |
Iron Sucrose injection, 1mg (Venofer) |
0.62 |
|
J1840 |
Kanamycin Sulfate, up to 500 mg (Kantrex, Klebcil) |
3.11 |
|
|
|
J1850 |
Kanamycin Sulfate, up to 75 mg (Kantrex, Klebcil) |
0.47 |
|
|
J1850 |
Kanamycin Sulfate, up to 75 mg (Kantrex, Klebcil) |
0.47 |
|
|
J1885 |
Ketorolac Tromethamine, per 15 mg (Toradol) |
3.38 |
|
J3490 |
Kutapressin, 1 ml |
7.65 |
|
|
* |
J3490 |
Laronidase, 2.9 mg/5 ml (Aldurazyme) |
699.75 |
|
J0640 |
Leucovorin Calcium , per 50 mg (Wellcovorin) |
3.52 |
|
|
|
J9219 |
Leuprolide Acetate Implant, 65 mg (Viadur) |
5115.60 |
|
* |
J3490 |
Leuprolide Acetate, 11.25 mg (Lupron Depot Pediatric) |
1166.26 |
|
* |
J3490 |
Leuprolide Acetate, 15 mg (Lupron, for Depot Pediatric) |
1284.51 |
|
|
J1950 |
Leuprolide Acetate, 3.5 mg (Lupron, for Depot Suspension) |
490.10 |
|
* |
J3490 |
Leuprolide Acetate, 7.5 mg (Lupron, for Depot Pediatric) |
642.39 |
|
|
J9217 |
Leuprolide Acetate, 7.5 mg (Lupron, for Depot Suspension) |
579.38 |
|
|
J9218 |
Leuprolide Acetate, per 1 mg (Lupron) |
66.58 |
|
|
J1955 |
Levocarnitine, per 1 gm (Carnitor) |
32.40 |
|
|
J1956 |
Levofloxacin, 250 mg (Levaquin) |
19.72 |
|
|
J1960 |
Levorphanol tartrate, up to 2 mg (Levo-Dromoran) |
3.56 |
|
|
J2001 |
Lidocaine HCL, 10 mg IV (Xylocaine) |
0.93 |
|
|
J2010 |
Lincomycin HCL, up to 300 mg (Lincocin) |
3.02 |
|
|
J2060 |
Lorazepam, 2 mg (Ativan) |
2.98 |
|
|
J3475 |
Magnesium Sulfate, 500 mg. |
0.25 |
|
|
J2150 |
Mannitol, 25% in 50 ml |
3.10 |
|
|
J9230 |
Mechlorethamine Hydrochloride (Nitrogen Mustard), 10mg |
11.38 |
|
|
J1055 |
Medroxyprogesterone Acetate for Contraceptive Use, 150 mg (Depo-Provera) |
53.06 |
|
|
J1051 |
Medroxyprogesterone Acetate, 50 mg (Depo-Provera) |
4.78 |
|
|
J1056 |
Medroxyprogesterone Acetate/Estradiol Cypionate 5 mg/25 mg (Lunelle) |
23.32 |
|
|
J9245 |
Melphalan Hydrochloride, 50 mg, (Alkeran) |
397.99 |
|
|
J2180 |
Meperidine and Promethazine HCL, up to 50 mg (Mepergan Injection) |
4.47 |
|
|
J2175 |
Meperidine Hydrochloride, per 100 mg (Demerol HCL) |
0.53 |
|
|
J0670 |
Mepivacaine, per 10 ml (Carbocaine) |
2.03 |
|
|
J9209 |
Mesna, 200 mg (Mesnex) |
34.56 |
|
|
J0380 |
Metaraminol Bitartrate, 10 mg (Aramine) |
1.21 |
|
|
J1230 |
Methadone HCL, up to 10 mg (Dolophine) |
0.71 |
|
|
J2800 |
Methocarbamol, up to 10 ml (Robaxin) |
14.00 |
|
|
J9250 |
Methotrexate Sodium, 5 mg |
0.37 |
|
|
J9260 |
Methotrexate Sodium, 50 mg |
4.50 |
|
|
J0210 |
Methyldopate HCL, up to 250 mg (Aldomet) |
11.26 |
|
|
J2210 |
Methylergonovine Maleate, up to 0.2 mg (Methergine) |
3.89 |
|
|
J1020 |
Methylprednisolone Acetate, 20 mg (Depo Medrol) |
2.54 |
|
|
J1030 |
Methylprednisolone Acetate, 40 mg |
3.92 |
|
|
J1040 |
Methylprednisolone Acetate, 80 mg |
7.84 |
|
|
J2930 |
Methylprednisolone Sodium Succinate, up to 125 mg (Solu-Medrol, A-methaPred) |
3.07 |
|
|
J2920 |
Methylprednisolone Sodium Succinate, up to 40 mg (Solu-Medrol, A-Metha Pred) |
1.85 |
|
|
J2765 |
Metoclopramide HCL, up to 10 mg (Reglan) |
1.88 |
|
|
J2250 |
Midazolam HCL, per 1 mg (Versed) |
1.22 |
|
|
J2260 |
Milrinone Lactate, 5 mg per 5 ml (Primacor) |
48.86 |
|
|
J9290 |
Mitomycin, 20 mg (Mutamycin) |
196.56 |
|
|
J9291 |
Mitomycin, 40 mg (Mutamycin) |
270.00 |
|
|
J9280 |
Mitomycin, 5 mg (Mutamycin) |
60.48 |
|
|
J9293 |
Mitoxantrone HCL, per 5 mg (Novantrone) |
340.43 |
|
|
J2271 |
Morphine Sulfate (100 mg) |
10.49 |
|
|
J2275 |
Morphine Sulfate (preservative-free sterile solution), per 10 mg (Astramorph PF, Duramorph) |
2.26 |
|
|
J2270 |
Morphine Sulfate, up to 10 mg |
0.73 |
|
|
J2310 |
Nalaxone HCL, per 1 mg (Narcan) |
2.24 |
|
|
J2300 |
Nalbuphine Hydrochloride, 10 mg |
1.43 |
|
|
J2321 |
Nandrolone Decanoate, up to 100 mg |
7.26 |
|
|
J2322 |
Nandrolone Decanoate, up to 200 mg |
14.91 |
|
|
J2320 |
Nandrolone Decanoate, up to 50 mg |
3.64 |
|
|
J2710 |
Neostigmine Methylsulfate, up to 0.5 mg (Prostigmin) |
0.64 |
|
|
J7030 |
Normal Saline Solution, 1000 cc, infusion |
10.21 |
|
|
J7050 |
Normal Saline Solution, 250 cc, infusion |
2.56 |
|
|
J7040 |
Normal Saline Solution, Sterile (500 ml=1 unit), infusion |
5.10 |
|
* |
J2353 |
Octreotide Acetate, 1 mg (Sandostatin LAR Depot), Pricing Based on 10 mg |
146.32 |
|
* |
J2353 |
Octreotide Acetate, 1 mg (Sandostatin LAR Depot), Pricing Based on 20 mg |
84.02 |
|
* |
J2353 |
Octreotide Acetate, 1 mg (Sandostatin LAR Depot), Pricing Based on 30 mg |
75.30 |
|
|
J2354 |
Octreotide Acetate, 25 mcg, non-depot, SC or IV |
4.03 |
|
|
S0107 |
Omalizumab 25mg (Xolair) |
81.19 |
|
|
J2405 |
Ondansetron Hydrochloride, per 1 mg (Zofran) |
5.77 |
|
|
J2355 |
Oprelvekin, 5 mg (Newmega) |
253.80 |
|
|
J2360 |
Orphenadrine Citrate, up to 60 mg (Norflex, etc.) |
5.14 |
|
|
J2700 |
Oxacillin Sodium, up to 250 mg (Bactocile, Prostaphlin) |
0.76 |
|
|
J9263 |
Oxaliplatin, 0.5 mg (Eloxatin) |
8.95 |
|
|
J2410 |
Oxymorphone HCL, up to 1 mg (Numorphan) |
2.80 |
|
|
J2460 |
Oxytetracycline HCL, up to 50 mg (Terramycin IM) |
0.96 |
|
|
J2590 |
Oxytocin, up to 10 units (Pitocin, Syntocinon) |
1.63 |
|
|
J9265 |
Paclitaxel, 30 mg (Taxol) |
155.45 |
|
|
J2430 |
Pamidronate Disodium, per 30 mg (Aredia) |
251.87 |
|
|
J2440 |
Papaverine HCL, up to 60 mg |
3.38 |
|
|
J9266 |
Pegaspargase Single Dose vial, (5 ml) (Oncaspar) |
1462.50 |
|
|
J2505 |
Pegfilgrastim, 6 mg (Neulasta) |
2655.00 |
|
|
J0540 |
Penicillin G Benzathine and Penicillin G Procaine, up to 1,200,000 units (Bicillin C-R) |
22.17 |
|
|
J0550 |
Penicillin G Benzathine and Penicillin G Procaine, up to 2,400,000 units (Bicillin C-R) |
47.48 |
|
|
J0530 |
Penicillin G Benzathine and Penicillin G procaine, up to 600,000 units (Bicillin C-R) |
11.30 |
|
|
J0570 |
Penicillin G Benzathine, up to 1,200,000 units (Bicillin L-A, Permapen) |
18.74 |
|
|
J0580 |
Penicillin G Benzathine, up to 2,400,000 units (Bicillin L-A, Permapen) |
37.48 |
|
|
J0560 |
Penicillin G Benzathine, up to 600,000 units (Bicillin L-A, Permapen) |
9.37 |
|
|
J2540 |
Penicillin G Potassium, up to 600,000 units (Pfizerpen) |
0.28 |
|
|
J2510 |
Penicillin G Procaine, Aqueous, up to 600,000 units (Wycillin, etc.) |
9.10 |
|
|
J2545 |
Pentamidine Isethionate, inhalation solution, per 300 mg (Pentam 300, NebuPent, PentacaRinat) |
48.10 |
|
|
S0080 |
Pentamidine Isethionate, IV, IM, per 300 mg |
42.48 |
|
|
J3070 |
Pentazocine HCL, up to 30 mg (Talwin) |
4.96 |
|
|
J2515 |
Pentobarbital Sodium (Nembutal Sodium Solution), per 50 mg |
1.25 |
|
|
J9268 |
Pentostatin, per 10 mg (Nipent) |
1825.20 |
|
|
J3310 |
Perphenazine, up to 5 mg (Trilafon) |
6.76 |
|
|
J2560 |
Phenobarbital Sodium, up to 120 mg |
1.54 |
|
|
J2760 |
Phentolamine Mesylate, up to 5 mg (Regitine) |
30.24 |
|
J2370 |
Phenylephrine HCL, up to 1 ml (NeoSynephrine) |
1.22 |
|
|
|
J1165 |
Phenytoin Sodium, per 50 mg (Dilantin) |
0.82 |
|
|
J2543 |
Piperacillin Sodium/Tazobactam Sodium 1gm/0.125 gm (1.125gm) (Zosyn) |
4.62 |
|
|
J9270 |
Plicamycin, 2.5 mg (Mithracin) |
88.87 |
|
|
J9600 |
Porfimer Sodium, 75 mg (Photofin) |
2466.64 |
|
|
J3480 |
Potassium Chloride, per 2 mEq. |
0.07 |
|
|
J2730 |
Pralidoxime Chloride, up to 1 gm (Protopam Chloride) |
97.54 |
|
|
J2650 |
Prednisolone Acetate, up to 1 ml |
0.30 |
|
|
J2690 |
Procainamide HCL, up to 1 gm (Pronestyl) |
1.36 |
|
|
J0780 |
Prochlorperazine Edisylate 10 mg (Compazine, Cotranzine, Compa-Z, Ultrazine-10) |
3.96 |
|
|
J2675 |
Progesterone, per 50 mg |
3.49 |
|
|
J2950 |
Promazine HCL, up to 25 mg (Sparine, Prozine-50) |
0.43 |
|
|
J2550 |
Promethazine HCL, up to 50 mg (Phenergan, Phenazine) |
2.70 |
|
|
J1800 |
Propranolol HCL, up to 1 mg (Inderal) |
11.02 |
|
|
J2720 |
Protamine Sulfate, per 10 mg |
0.72 |
|
|
J2725 |
Protirelin, per 250 mcg (Relefact TRH, Thypinone) |
23.11 |
|
|
J2780 |
Rantidine HCL, 25 mg (Zantac) |
1.36 |
|
|
J2993 |
Retaplase, 18.1 mg (Retavase) |
1292.63 |
|
|
J7120 |
Ringers Lactate Infusion, up to 1000 cc |
11.80 |
|
* |
J3490 |
Risperidone 25mg (Risperdal Consta) |
249.84 |
|
* |
J3490 |
Risperidone 37.5mg (Risperdal Consta) |
374.77 |
|
* |
J3490 |
Risperidone 50mg (Risperdal Consta) |
499.69 |
|
|
J9310 |
Rituximab (Rituxan) 100 mg (Rituxan) |
474.76 |
|
|
J2820 |
Sargramostim (GM-CSF), 50 mcg (Leukine, Prokine) |
27.53 |
|
J3490 |
Sodium Bicarbonate 7.5% up to 50 ml |
3.20 |
|
|
J2912 |
Sodium Chloride, 0.9% per 2 ml |
0.47 |
|
|
|
J2916 |
Sodium Ferric Gluconate Complex in Sucrose, 12.5mg (Ferrlecit) |
7.74 |
|
J7317 |
Sodium Hyaluronate, per 20-25 mg. for intra-articular injection (Biolon, Provisc, Vitrax, Hyalgan) |
131.41 |
|
|
|
J3320 |
Spectinomycin Dihydrochloride, up to 2 gm (Trobicin) |
26.78 |
|
|
J7051 |
Sterile Saline or Water (up to 5 cc) |
0.72 |
|
|
J2995 |
Streptokinase, per 250,000 IU (Streptase) |
84.38 |
|
|
J3000 |
Streptomycin, up to 1 gm (Streptomycin Sulfate) |
6.01 |
|
J9320 |
Streptozocin, 1 gm (Zanosar) |
134.03 |
|
|
J0330 |
Succinycholine Chloride, up to 20 mg (Anectine, Quelicin, Surostrin) |
0.19 |
|
|
J3105 |
Terbutaline Sulfate, up to 1 mg (Brethine, Bricanyl Subcutaneous) |
27.85 |
|
|
J1060 |
Testosterone Cypionate and Estradiol Cypionate, up to 1 ml |
4.40 |
|
|
J1070 |
Testosterone Cypionate, up to 100 mg |
4.69 |
|
|
J0900 |
Testosterone Enanthate and Estradiol Valerate up to 1 cc (Deladumone, etc.) |
1.55 |
|
|
J3120 |
Testosterone Enanthate, up to 100 mg (Evarone, Delatestryl, etc.) |
8.51 |
|
|
J3130 |
Testosterone Enanthate, up to 200 mg, (Evarone, Delatestryl, Andro L.A. 200, etc.) |
17.02 |
|
|
J1080 |
Testosterone Estradiol Cypionate, 1 cc, 200 mg |
8.94 |
|
|
J3150 |
Testosterone Propionate, up to 100 mg (Testex) |
1.62 |
|
|
J3140 |
Testosterone Suspension, up to 50 mg (Andronaq 50, Testosterone Aqueous, etc.) |
0.38 |
|
|
|
J0120 |
Tetracycline, up to 250 mg (Achromycin, Panmycin, Sumycin) |
0.23 |
|
J3280 |
Thiethylperazine Maleate, up to 10 mg (Norzine, Torecan) |
5.36 |
|
|
J9340 |
Thiotepa, 15 mg (Thioplex) |
110.82 |
|
|
J3240 |
Thyrotropin Alfa, 0.9 mg (Thyrogen) |
585.00 |
|
|
J3260 |
Tobramycin Sulfate, up to 80 mg (Nebcin) |
4.22 |
|
|
J2670 |
Tolazoline HCL, up to 25 mg (Priscoline HCL) |
3.72 |
|
|
J9350 |
Topotecan, 4 mg (Hycamtin) |
756.61 |
|
|
J3265 |
Torsemide, 10 mg/ml (Demadex) |
1.48 |
|
|
J9355 |
Trastuzumab, 10 mg (Herceptin) |
55.07 |
|
|
J3301 |
Triamcinolone Acetonide, per 10 mg (Kenalog-10, Kenalog-40, Tri-Kort, etc.) |
1.51 |
|
|
J3302 |
Triamcinolone Diacetate, per 5 mg (Aristocort Intralesional, Aristocort Forte, Amcort, etc.) |
0.32 |
|
|
J3303 |
Triamcinolone Hexacetonide, per 5 mg (Aristospan Intralesional, Aristospan Intra-articular) |
0.95 |
|
|
J3400 |
Triflupromazine HCL, up to 20 mg (Vesprin) |
11.70 |
|
|
J3250 |
Trimethobenzamide HCL, up to 200 mg (Tigan, Ticon, Tiject-20, Arrestin) |
1.47 |
|
|
J3305 |
Trimetrexate Glucoronate, per 25 mg (Neutrexin) |
135.00 |
|
|
J3350 |
Urea, up to 40 gm (Ureaphil) |
80.00 |
|
|
J3365 |
Urokinase, 250,000 I.U. Vial (Abbokinase) |
484.58 |
|
|
J3364 |
Urokinase, 5000 I.U. vial (Abbokinase Open-Cath) |
9.69 |
|
|
|
J9357 |
Valrubicin, intravesical, 200 mg (Valstar) |
498.96 |
|
|
J3370 |
Vancomycin HCL, 500 mg (Varcocin, Vancoled) |
6.66 |
|
|
J9360 |
Vinblastine Sulfate, 1 mg (Velban) |
3.89 |
|
|
J9370 |
Vincristine Sulfate, 1 mg (Oncovin,) |
32.19 |
|
|
J9375 |
Vincristine Sulfate, 2 mg (Oncovin) |
64.39 |
|
|
J9380 |
Vincristine Sulfate, 5 mg (Oncovin,) |
151.92 |
|
|
J9390 |
Vinorelbine Tartrate, per 10 mg (Navelbine) |
84.65 |
|
|
J3430 |
Vitamin K, Phytonadione 1 mg/0.5ml |
2.30 |
|
|
J2501 |
Zemplar (Paricalcitol) 1 mcg |
4.75 |
|
|
J3487 |
Zoledronic Acid (Zometa), 1 mg |
205.98 |
Note: The following list of drugs has been added since April 2004 bulletin or the code number and/or fee has changed since April 2004. The fees listed for these drugs are current as of the date of this publication.
|
Invoice Required |
Procedure Code |
Description |
Maximum Reimbursement Rate |
|---|---|---|---|
|
* |
J9999 |
Azacitidine (Vidaza) 25 mg |
$107.40 |
|
S0159 |
Agalsidase Beta, 35mg(Fabrazyme) |
4500.00 |
|
|
S0116 |
Bevacizumab (Avastin) 100 mg |
618.75 |
|
|
* |
J9999 |
Cetuximab (Erbitux) 100 mg/50 ml vial |
489.60 |
|
J9300 |
Gemtuzumab ozogamicin (Mylotarg) 5 mg |
1953.94 |
|
|
S0158 |
Laronidase (Aldurazyme) .58 mg |
139.95 |
|
|
* |
J9999 |
Pemetrexed (Alimta) 500 mg |
2071.88 |
|
S0163 |
Risperidone, long acting (Risperdal Consta) 12.5 mg |
124.92 |
|
|
|
J3395 |
Verteporfin (Visudyne) 15 mg |
1404.26 |
Immune Globulins
|
Invoice Required |
Procedure Code |
Description |
Maximum Reimbursement Rate |
|---|---|---|---|
|
|
90291 |
Cytomegalovirus immune globulin (CMV-IgIV), human, for intravenous use, 1 ml |
$13.49 |
|
|
J1460 |
Gamma Globulin, Intramuscular, 1 cc (Gammar) |
11.53 |
|
|
J1470 |
Gamma Globulin, Intramuscular, 2 cc |
23.07 |
|
|
J1480 |
Gamma Globulin, Intramuscular, 3 cc |
34.63 |
|
|
J1490 |
Gamma Globulin, Intramuscular, 4 cc |
46.13 |
|
|
J1500 |
Gamma Globulin, Intramuscular, 5 cc |
57.66 |
|
|
J1510 |
Gamma Globulin, Intramuscular, 6 cc |
69.05 |
|
|
J1520 |
Gamma Globulin, Intramuscular, 7 cc |
80.64 |
|
|
J1530 |
Gamma Globulin, Intramuscular, 8 cc |
92.26 |
|
|
J1540 |
Gamma Globulin, Intramuscular, 9 cc |
103.89 |
|
|
J1550 |
Gamma Globulin, Intramuscular, 10 cc |
115.32 |
|
|
J1560 |
Gamma Globulin, Intramuscular, over 10 cc (use correct combinations of above codes) |
^^ |
|
|
90371 |
Hepatitis B immune globulin (HBIg), human, for intramuscular use, 0.5 ml |
615.6 |
|
|
J1563 |
Immune Globulin, Intravenous, 1 gm (Sandoglobulin) |
82.24 |
|
|
J1564 |
Immune Globulin, Intravenous, 10 mg (Sandoglobulin) |
0.82 |
|
|
90375 |
Rabies immune globulin (RIg), human, for intramuscular and/or subcutaneous use, 2 ml |
69.01 |
|
|
90376 |
Rabies immune globulin, heat-treated (RIg-HT), human, for intramuscular and/or subcutaneous use, 2 ml |
74.00 |
|
|
90379 |
Respiratory syncytial virus immune globulin (RSV-IgIV), human, for intravenous use, 1 ml |
17.17 |
|
|
90384 |
Rho(D) immune globulin (RhIg), human, full-dose, for intramuscular use, 1500 IU/300 mcg |
95.04 |
|
|
90385 |
Rho(D) immune globulin (RhIg), human, mini-dose, for intramuscular use, 120 IU/50 mcg |
32.94 |
|
|
90386 |
Rho(D) immune globulin (RhIglV), human, for intravenous use, 100 IU |
20.10 |
|
|
90389 |
Tetanus immune globulin (TIg), human, for intramuscular use, 250 u/1 ml |
118.13 |
|
|
90396 |
Varicella-zoster immune globulin, human, for intramuscular use, 125 u/1.25 ml |
112.50 |
(^ ^) Designates special pricing.
Vaccines/Toxoids
Medicaid reimburses for vaccines in accordance with the guidelines from the Advisory Committee on Immunization Practices (ACIP). Information regarding the risk categories pertinent to vaccines may be found at http://www.cdc.gov/nip/ACIP/default.htm.
Medicaid does not reimburse for vaccines provided to recipients ages birth through 18 years that are available through the Universal Childhood Vaccine Distribution Program (UCVDP)/Vaccines for Children (VFC) Program. For Medicaid-eligible recipients ages 19 through 20 who are not age-eligible for the VFC program vaccines, Medicaid will reimburse providers for Medicaid-covered vaccines.
Vaccines/Toxoids Drug List
|
Invoice Required |
Procedure Code |
Description |
Maximum Reimbursement Rate |
|---|---|---|---|
|
|
90585 |
Bacillus Calmette-Guerin vaccine (BCG), for tuberculosis, live, for percutaneous use, per vial |
$151.70 |
|
|
90721 |
Diphtheria, tetanus toxoids, and acellular pertussis vaccine and Hemophilus influenza B vaccine (DtaP-Hib), for intramuscular use |
46.27 |
|
|
90647 |
Hemophilus influenza b vaccine (Hib) PRP-OMP conjugate (3 Dose schedule), for intramuscular use, 0.5 ml |
21.52 |
|
|
90648 |
Hemophilus influenza b vaccine (Hib) PRP-T conjugate (4 dose schedule), for intramuscular use, 0.5 ml |
22.86 |
|
|
90632 |
Hepatitis A vaccine, adult dosage, for intramuscular use, 1ml |
66.65 |
|
|
90633 |
Hepatitis A vaccine, pediatric/adolescent dosage-2 dose schedule, for intramuscular use, 0.5 ml |
28.22 |
|
|
90746 |
Hepatitis B vaccine, adult dosage, for intramuscular use, 1 ml |
52.54 |
|
|
90747 |
Hepatitis B vaccine, dialysis or immunosuppressed patient dosage (4 dose schedule), for intramuscular use, 40 mcg/2ml per dose |
105.08 |
|
|
90658 |
Influenza virus vaccine, split virus, 3 years and above dosage, for intramuscular or jet injection use, 0.5 ml |
9.42 |
|
|
90705 |
Measles virus vaccine, live, for subcutaneous or jet injection use, 0.5 ml |
14.24 |
|
|
90707 |
Measles, mumps and rubella virus vaccine (MMR), live, for subcutaneous or jet injection use |
36.98 |
|
|
90733 |
Meningococcal polysaccharide vaccine (any group(s)), for subcutaneous or jet injection use, 0.05 mg |
62.11 |
|
|
90704 |
Mumps virus vaccine, live, for subcutaneous or jet injection use |
$18.41 |
|
|
90732 |
Pneumococcal polysaccharide vaccine, 23-valent, adult or immunosuppressed patient dosage, for use in individuals 2 years or older, for subcutaneous or intramuscular use, 0.5 ml |
17.64 |
|
|
90713 |
Poliovirus vaccine, inactivated, (IPV), for subcutaneous use |
24.35 |
|
|
90675 |
Rabies vaccine, for intramuscular use, 2 ml |
129.00 |
|
|
90680 |
Rotavirus vaccine, tetravalent, live, for oral use |
17.37 |
|
|
90706 |
Rubella virus vaccine, live, for subcutaneous or jet injection use, 0.5 ml |
15.85 |
|
90718 |
Tetanus and diphtheria toxoids (Td) adsorbed for use in individuals seven years or older, for intramuscular or jet injection, 0.5 ml |
10.92 |
|
|
90703 |
Tetanus toxoid adsorbed, for intramuscular or jet injection use, 0.5 ml |
13.62 |
|
|
90716 |
Varicella virus vaccine, live, for subcutaneous use, 0.5 ml |
61.26 |
Aydlett Hunike, Financial Management
DMA, 919-855-4200
Effective January 1, 2005, physician-type providers will enroll directly with the Division of Medical Assistance to participate in the Medicaid program. Blue Cross Blue Shield of North Carolina has processed enrollment for these practitioners for many years, but will no longer do so after December 31, 2004.
By December 1, 2004, applications, agreements, change forms and instructions will be available on the DMA website. Physician-type providers will be able to download these forms to enroll in the Medicaid program. They will also be able to change their existing enrollment information, including addresses, by downloading and completing DMA enrollment change forms from the DMA website.
If you have questions about this change in procedure, please contact DMA Provider Services.
Angela Floyd, Provider Services
DMA, 919-855-4050
Legislation was passed July 1, 2004 removing anorexia, weight loss and weight gain products from the N.C. Medicaid Pharmacy Program. On September 28, 2004, all weight loss products were end-dated to non-coverage status, with an effective date of July 1, 2004 (claims previously paid will not be recouped). N.C. Medicaid will deny claims for weight loss drugs: (J8A - Anorexic Agents, D5A - Fat Absorption Decreasing Agents) including Meridia and Xenical.
Sharman Leinwand, Pharmacy Manager
DMA, 919-855-4260
Due to the voluntary withdrawl of Vioxx from the U.S. and worldwide market by Merck & Co., Inc., effective with date of service October 1, 2004, the N.C. Medicaid program end-dated coverage for all forms of Vioxx.
Prior approval overrides will not be issued by the N.C. Medicaid program for Vioxx. Individual prescribers must prescribe an alternative medication for their patients.
Sharman Leinwand, Pharmacy Manager
DMA, 919-855-4260
Effective with date of service August 24, 2004, the medical necessity criteria for the approval of Oxycontin was revised to address the following situations.
Criteria for Cancer or Patients with Other Terminal Illnesses
Criteria for Chronic, Nonmalignant Pain
Additional information, including prior authorization criteria, frequently asked questions, and prior authorization forms is available online at http://www.ncmedicaidpbm.com.
EDS, 1-800-688-6696 or 919-851-8888
Effective with date of service August 24, 2004, the medical necessity criteria for the approval of modafinil (Provigil) was revised.
Approval of Provigil is considered as a treatment to improve wakefulness for patients who:
The maximum daily dose should be two tablets per day for all strengths.
Additional information, including prior authorization criteria, frequently asked questions, and prior authorization forms is available online at http://www.ncmedicaidpbm.com.
EDS, 1-800-688-6696 or 919-851-8888
Effective with date of service August 25, 2004, the following smoking cessation medications and products no longer require prior authorization from Medicaid:
There is no limit to the number of times a recipient can receive these medications and products.
EDS, 1-800-688-6696 or 919-851-8888
The Criteria 1a-1d form for Synagis has been revised to correct an error in the date of birth requirement for patients with Hemodynamically Significant Heart Disease. The date of birth for this group of patients must be on or after October 15, 2002, which will allow receipt of Synagis for patients 24 months or younger. This change is consistent with the Red Book 2003 guidelines as follows:
"Children who are 24 months of age or younger with hemodynamically significant cyanotic and acyanotic congenital heart disease will benefit from 5 monthly intramuscular injections of palivizumab (15mg/kg). Decisions regarding prophylaxis with palivizumab in children with congenital heart disease should be made on the basis of the degree of physiologic cardiovascular compromise. Infants younger than 12 months of age with congenital heart disease who are most likely to benefit from immunoprophylaxis include:
Also, there has been some confusion regarding requirements for prematurity in criteria 1a. Chronic Lung Disease is the same as Bronchopulmonary Dysplasia (BPD) which is generally a lung disease of prematurity. This is not asthma.
Synagis Policies and Procedure for the RSV season 2004-2005.
Sharman Leinwand, Pharmacy Manager
DMA, 919-855-4260
Prior approval for stem cell transplants will only be effective for a six month period, from the date the prior approval is granted. If services extend beyond the six month period, providers will need to notify the hospital consultant, and a new request, along with additional clinical information may be requested.
Debbie Garrett, RNC, Hospital Consultant
Clinical Policy and Programs
DMA, 919-857-4020
The proposed CAP-MR/DD rates and service changes to be effective April 1, 2005, have been published on the following web sites as of October 19, 2004:
These rates are based on the service definitions contained within the CAP-MR/DD waiver posted on the DMH/DD/SAS web site.
In arriving at the proposed CAP-MR/DD Medicaid rates, there were some new services added as well as other services being eliminated based on the new waiver. Service rates were updated for increases which had occurred across all specialties regarding personal care and nurse visits. Additionally, multiple cost models for the new services were developed that factored in direct labor costs, supervisory labor costs, supply costs, and other administrative costs. Subject matter experts were consulted and asked for input into the calculations of the cost models. Once all of this data was collected, the rate setting staff of DMA and the DMH/DD/SAS jointly reviewed the forecasted volume of service costs and the cost models and agreed on rates and anticipated utilizations to arrive at the proposed CAP-MR/DD Medicaid rates.
The Department of Health and Human Services is appreciative of and welcomes input regarding these proposed rates prior to finalization. In order to effectively address and respond to concerns regarding these rates, it is necessary for DMA, DMH/DD/SAS and the Controller’s Office to focus on issues brought to us from a representative sample of actual service providers. For consideration of any discussion of the new proposed rates, DMA, DMH/DD/SAS, and Controller’s Office rate setting staff will seek data and analyses from at least three providers for each service for comparison. This data must include the assumptions and the calculations to arrive at cost figures from financial statements which need to accompany the cost data.
The selection of providers to submit cost data will be performed in a new manner. The selection of providers will come from a provider database being developed by DMH/DD/SAS. DMH/DD/SAS and DMA will select a representative sample of providers from the providers currently listed in the provider database in addition to specific provider recommendations from various provider organizations in order to review the attached proposed rates for implementation April 1, 2005. The process will bring together the providers with DMA, DMH/DD/SAS and Controller’s Office staff to walk through the new services and rates. If providers disagree with any of the proposed rates, they will have the opportunity to submit data to DMA, DMH/DD/SAS and the Controller’s Office, as described above, for the purpose of rate reconsideration. The participating providers will have until November 19, 2004 to submit their cost data. The providers selected for this review process will be listed on each Division’s web page. Following this review, final rates will be presented to the DHHS Rate Review Board for approval and implementation.
In the future, it is our intent for the provider database to become more comprehensive. The database will consist of providers who have expressed a willingness to participate with DHHS staff in future meetings around rate and policy issues. This database will be developed as follows:
DMA and DMH/DD/SAS will make development of the provider listing an open and widely publicized process to ensure that all providers who are willing to participate have the opportunity to sign up. By rotating provider participation around subsequent rate and policy issues, DHHS will seek to broaden provider representation and input into the various rate and policy issues which impact MH/DD/SA service development and operation. Rotation of provider representation will also help ensure that providers with relevant experience are involved in related rate and policy issues.
Jamie Christensen, Rate Setting
DMA, 919-855-4200
The proposed Enhanced Benefits and existing Mental Health Service rates to be effective July 1, 2005, have been published on the following web sites as of October 19, 2004 on:
The rates are based on the service definitions posted on the DMHDDSAS web site
In arriving at the proposed FY 2006 Medicaid rates, there were many factors that were considered in the calculation methodologies. The first factor was taking historical actual claims paid in FY 2003 multiplied by the rate in place for FY 2004 to give a real expended figure for projection into the new service definitions established jointly by DMA and DMH/DD/SAS. This volume of service costs was cross walked into the new service definitions with an anticipated utilization developed by DMH/DD/SAS. In addition to referencing rate information provided by TAC, multiple cost models were developed that factored in direct labor costs, supervisory labor costs, supply costs, and other administrative costs. Subject matter experts in all areas of service delivery were polled and asked for input into the calculations of the numerous cost models. Once all of this data was collected, the rate setting staff of DMA and the DMH/DD/SAS jointly reviewed the forecasted volume of service costs and the cost models and agreed on rates and anticipated utilizations to arrive at the proposed FY 2006 Medicaid rates.
The Department of Health and Human Services is appreciative of and welcomes input regarding these proposed rates prior to finalization. In order to effectively address and respond to concerns regarding these rates, it is necessary for DMA, DMH/DD/SAS and the Controller’s Office to focus on issues brought to us from a representative sample of actual service providers. For consideration of any discussion of the new proposed rates, DMA, DMH/DD/SAS and the Controller’s Office rate setting staff will seek data and analyses from at least three providers for each service for comparison. This data must include the assumptions and the calculations to arrive at cost figures from financial statements which must accompany the cost data.
The selection of providers to submit cost data will be performed in a new manner. The selection of providers will come from a provider database being developed by DMH/DD/SAS. We find this is necessary since many providers currently bill for services through area programs; thus they are not visible to the State. DMH/DD/SAS and DMA will select a representative sample of providers from the providers currently listed in the provider database in addition to specific provider recommendations from various provider organizations in order to review the attached proposed rates for implementation July 1, 2005. The process will bring together the providers with DMA, DMH/DD/SAS and the Controller’s Office staff to walk through the new services and rates. If providers disagree with any of the proposed rates, they will have the opportunity to submit data to DMA, DMH/DD/SAS and the Controller’s Office, as described above, for the purpose of rate reconsideration. The participating providers will have until November 19, 2004 to submit their cost data. The providers selected for this review process will be listed on each Division’s web page. Following this review, final rates will be presented to the DHHS Rate Review Board for approval and implementation.
In the future, it is our intent for the provider database to become more comprehensive. The database will consist of providers who have expressed a willingness to participate with DHHS staff in future meetings around rate and policy issues. This database will be developed as follows:
1. DMH/DD/SAS and DMA will send out a communication to providers, provider organizations, LMEs, etc., prior to November 1, 2004, informing them of the provider database and indicating how providers can express their willingness to participate;
2. DMH/DD/SAS will set up the database on its public web page through which providers can indicate their willingness to participate by entering the required provider information such as, services provided, agency budget, sources of revenues, incorporation status of the provider, number of consumers served, etc.
DMA and DMH/DD/SAS will make development of the provider listing an open and widely publicized process to ensure that all providers who are willing to participate have the opportunity to sign up. By rotating provider participation around subsequent rate and policy issues, DHHS will seek to broaden provider representation and input into the various rate and policy issues which impact MH/DD/SA service development and operation. Rotation of provider representation will also help ensure that providers with relevant experience are involved in related rate and policy issues.
In addition this bulletin, the same communications were sent on October 19, 2004, to Area/County MHDDSAS Directors, and various providers, stakeholders and professional organizations.
Bill Connelly, Rate Setting
DMA, 919-855-4200
Effective immediately, ValueOptions has revised their Outpatient Treatment Report. This form will reflect utilization of H codes and CPT codes. Providers can access these forms on the web at http://www.ValueOptions.com.
Carolyn Wiser, Behavioral Health Services
DMA, 919-855-4290
Effective with date of service October 1, 2004, the maximum allowable rate for the following hospice services are outlined below:
|
Routine Home Care |
Continuous Home Care |
Inpatient Respite Care |
General Inpatient Care |
|||
|
Metropolitan Statistical Area |
SC |
MSA |
RC 651 Daily |
RC 652 Hourly |
RC 655 Daily |
RC 656 Daily |
|
Asheville |
39 |
480 |
125.16 |
30.41 |
135.41 |
555.11 |
|
Charlotte/Gastonia/Rock Hill |
41 |
1520 |
125.51 |
30.49 |
135.71 |
556.57 |
|
Fayetteville |
42 |
2560 |
118.59 |
28.81 |
129.78 |
527.92 |
|
Greensboro/Winston-Salem/High Point |
43 |
3120 |
120.20 |
29.20 |
131.16 |
534.59 |
|
Hickory/Morganton/Lenoir |
44 |
3290 |
120.88 |
29.37 |
131.74 |
537.40 |
|
Jacksonville |
45 |
3605 |
114.64 |
27.85 |
126.39 |
511.56 |
|
Raleigh/Durham/Chapel Hill |
46 |
6640 |
127.29 |
30.93 |
137.23 |
563.94 |
|
Wilmington |
47 |
9200 |
123.75 |
30.07 |
134.20 |
549.28 |
|
Rural Counties |
53 |
9934 |
113.87 |
27.67 |
125.74 |
508.40 |
|
Goldsboro |
105 |
2980 |
115.33 |
28.02 |
126.99 |
514.44 |
|
Greenville |
106 |
3150 |
119.60 |
29.06 |
130.64 |
532.09 |
|
Norfolk (Currituck County) |
107 |
5720 |
115.31 |
28.02 |
126.97 |
514.34 |
|
Rocky Mount |
108 |
6895 |
119.40 |
29.01 |
130.47 |
531.25 |
At this time, the rate for RC 659 is still reimbursed at $131.14
Key to the Hospice Rate Table
|
SC |
Specialty Code |
|
RC |
Revenue Code |
EDS, 1-800-688-6696 or 919-851-8888
North Carolina faces a shortage of influenza vaccine this year due to the loss of approximately one half of the United States supply of trivalent inactivated vaccine for the 2004-2005 influenza season. As a result of this shortage, the N.C. Medicaid program and the N.C. Division of Public Health are following the CDC’s recommendations for prioritizing the use of the remaining vaccine supplies.
CDC urges vaccination of the following priority groups:
Information regarding the risk categories pertinent to influenza vaccine can be accessed online at http://www.cdc.gov/nip/ACIP/default.htm.
FluMist Nasal Vaccine
The N.C. Medicaid program is also responding to the vaccine shortage by covering the FluMist nasal vaccine for healthy recipient’s ages 5 years through 49 years who are household contacts of medically high-risk Medicaid recipients. The coverage is effective with date of service October 1, 2004. FluMist is only covered when it is dispensed at the local health department according to the guidelines from the Advisory Committee on Immunization Practices. This policy will remain in effect through March 31, 2005.
The inactivated influenza vaccine is preferred over LAIV, known commercially as FluMist, for household members, health-care workers, and others who have close contact with severely immunosupressed persons (e.g., patients with hepatopoietic stem cell transplants) during those periods when the person requires care in a protective environment.
No preference exists, however, for inactivated influenza vaccine use by some members of the last two high-risk groups mentioned above. Health-care workers providing direct patient care, and out-of-home caregivers and household contacts of children aged <6 months may be candidates for the FluMist vaccine.
The following people should not receive the intranasal influenza vaccine (FluMist).
Reimbursement Guidelines
Reimbursement for the Injectable Vaccine for Recipients through Age 18
The Immunization Branch distributes childhood vaccines to local health departments, hospitals, and private providers to be used in accordance with the N.C. Universal Childhood Vaccine Distribution Program/Vaccine for Children (UCVDP/VFC) coverage criteria and state law/administrative code. The N.C. Medicaid program does not routinely reimburse for vaccines that are supplied through UCVDP/VFC for recipients through 18 years of age. However, due to the shortage of the influenza vaccine for the 2004-2005 flu season, Medicaid will reimburse providers who have purchased a supply of the injectable vaccine because the supply of free vaccine has been exhausted when it is used for recipients through 18 years of age. Reimbursement for purchased vaccine will be made for dates of service October 1, 2004 through March 31, 2005.
Changes are underway to allow for processing of claims for the purchased injectable vaccine. Providers should watch future bulletins for notification that the system is prepared to accept claims.
Reimbursement for the Injectable Vaccine for Recipients 19 Years of Age and Older
Providers may bill Medicaid for influenza vaccine for high-risk adults 19 and 20 years of age using CPT code 90658. Refer to the 2004 Health Check Special Bulletin, page 7, for billing guidelines.
All providers may bill Medicaid for influenza vaccine for high-risk adults > 19 years of age using CPT code 90658 and for the administration fee using CPT code 90471. An Evaluation and Management (E/M) code cannot be reimbursed to any provider on the same day that injection administration fee codes (90471, or 90471 and 90472) are reimbursed, unless the provider bills an E/M code for a separately identifiable service by appending modifier 25 to the E/M code.
Reimbursement for FluMist Vaccine
Changes are underway to allow for processing of Local Health Department claims for FluMist. An administration fee will not be reimbursed in addition to the cost of the vaccine. Providers should watch future Medicaid bulletins for notification that the system is prepared to accept claims. FluMist will be reimbursed only when administered at the Local Health Department.
Billing Reminders for Vaccine Supplied Through VFC
Medicaid does not reimburse for influenza vaccine that is supplied through UCVDP/VFC for recipients through 18 years of age. Report CPT code 90655 or 90657 for children < 6 months through 35 months of age and CPT code 90658 for children > 3 years of age through 18 years of age.
Providers may bill for an administration fee using CPT code 90471 or 90471 and 90472, as appropriate. Local health departments, however, may only bill CPT code 90471 with the EP modifier for any visit other than a Health Check screening. Refer to the 2004 Health Check Special Bulletin, page 7, for billing guidelines.
EDS, 1-800-688-6696 or 919-851-8888
In accordance with Session Law 2003-284, proposed new or amended Medicaid clinical coverage policies are available for review and comment on DMA’s website. To submit a comment related to a policy, refer to the instructions on the website. Providers without Internet access can submit written comments to the address listed below.
Gina Rutherford
Division of Medical Assistance
Clinical Policy Section
2501 Mail Service Center
Raleigh, NC 27699-2501
The initial comment period for each proposed policy is 45 days. An additional 15-day comment period will follow if a proposed policy is revised as a result of the initial comment period.
The Division of Medical Assistance (DMA) and EDS will be closed on Thursday, November 11, 2004 in observance of Veteran’s Day and on Thursday, November 25, 2004 and Friday, November 26, 2004 in observance of Thanksgiving.
|
November 2, 2004 |
December 7, 2004 |
|
November 9, 2004 |
December 14, 2004 |
|
November 16, 2004 |
December 22, 2004 |
|
November 24, 2004 |
|
October 29, 2004 |
December 3, 2004 |
|
November 5, 2004 |
December 10, 2004 |
|
November 12, 2004 |
December 17, 2004 |
|
November 19, 2004 |
Electronic claims must be transmitted and completed by 5:00 p.m. on the cut-off date to be included in the next checkwrite. Any claims transmitted after 5:00 p.m. will be processed on the second checkwrite following the transmission date.
|
_____________________
|
_____________________
|
|
|
Gary H. Fuquay, Director
|
Cheryll Collier
|
|
|
Division of Medical Assitance
|
Executive Director
|
|
|
Department of Health and Human Services
|
EDS
|
| DMA Home | Top |